AU2010234641B2 - Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer - Google Patents

Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer Download PDF

Info

Publication number
AU2010234641B2
AU2010234641B2 AU2010234641A AU2010234641A AU2010234641B2 AU 2010234641 B2 AU2010234641 B2 AU 2010234641B2 AU 2010234641 A AU2010234641 A AU 2010234641A AU 2010234641 A AU2010234641 A AU 2010234641A AU 2010234641 B2 AU2010234641 B2 AU 2010234641B2
Authority
AU
Australia
Prior art keywords
compound
decitabine
cancer
ester
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010234641A
Other languages
English (en)
Other versions
AU2010234641A1 (en
Inventor
Sergei Belyakov
Bridget Duvall
Dana Ferraris
Gregory Hamilton
Mark Vaal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of AU2010234641A1 publication Critical patent/AU2010234641A1/en
Assigned to OTSUKA PHARMACEUTICAL CO., LTD. reassignment OTSUKA PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: EISAI INC.
Application granted granted Critical
Publication of AU2010234641B2 publication Critical patent/AU2010234641B2/en
Assigned to TAIHO PHARMACEUTICAL CO., LTD. reassignment TAIHO PHARMACEUTICAL CO., LTD. Request for Assignment Assignors: OTSUKA PHARMACEUTICAL CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010234641A 2009-04-06 2010-04-06 Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer Active AU2010234641B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16711909P 2009-04-06 2009-04-06
US61/167,119 2009-04-06
PCT/US2010/030078 WO2010118010A1 (en) 2009-04-06 2010-04-06 Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer

Publications (2)

Publication Number Publication Date
AU2010234641A1 AU2010234641A1 (en) 2011-11-10
AU2010234641B2 true AU2010234641B2 (en) 2016-04-21

Family

ID=42357480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010234641A Active AU2010234641B2 (en) 2009-04-06 2010-04-06 Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer

Country Status (11)

Country Link
US (1) US8329666B2 (enExample)
EP (1) EP2416780B1 (enExample)
JP (1) JP5730854B2 (enExample)
AR (1) AR076263A1 (enExample)
AU (1) AU2010234641B2 (enExample)
CA (1) CA2757744C (enExample)
ES (1) ES2628580T3 (enExample)
JO (1) JO3262B1 (enExample)
TW (1) TWI503121B (enExample)
UY (1) UY32546A (enExample)
WO (1) WO2010118010A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2870937B2 (ja) 1990-02-26 1999-03-17 凸版印刷株式会社 金属蒸着フィルムの製造方法
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
AR076262A1 (es) * 2009-04-06 2011-06-01 Eisai Inc Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
JP5684787B2 (ja) * 2009-04-06 2015-03-18 大塚製薬株式会社 シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
CA3007357C (en) 2015-12-03 2023-12-05 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
ES2905478T3 (es) 2016-12-28 2022-04-08 Transgene Sa Virus oncolíticos y moléculas terapéuticas
US11224610B2 (en) 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
US11911610B2 (en) 2019-03-29 2024-02-27 Novocure Gmbh Methods for restoring sensitivity to TTFields in TTFields-resistant cancer cells with PTGER3 inhibitors
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US5464826A (en) * 1984-12-04 1995-11-07 Eli Lilly And Company Method of treating tumors in mammals with 2',2'-difluoronucleosides
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1985001871A1 (en) 1983-10-26 1985-05-09 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US5223608A (en) * 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
FR2682112B1 (fr) * 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) * 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) * 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) * 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5606048A (en) * 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) * 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
DE69403588T2 (de) * 1993-02-23 1998-01-22 Hope City 4-ethoxy-5-fluor-2'-deoxyuridine
AU6081294A (en) 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) * 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) * 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) * 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
DK1156827T3 (da) 1999-03-01 2007-02-05 Halogenetics Inc Anvendelse af sammensætninger omfattende CldC som strålingssensibilisatorer ved behandlingen af neoplastiske sygdomme
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
EP1348712B1 (en) 2000-11-29 2011-05-04 Mitsui Chemicals, Inc. Processes and intermediates in the synthesis of L-thymidine
WO2002056912A2 (en) * 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
US7589077B2 (en) 2001-05-18 2009-09-15 Rakesh Kumar Antiviral nucleosides
EP1545558A4 (en) 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US8158770B2 (en) * 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
WO2006015346A1 (en) 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
JP2007522151A (ja) 2004-12-08 2007-08-09 シコール インコーポレイティド ジフルオロヌクレオシド及びその調製方法
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
JP5684787B2 (ja) * 2009-04-06 2015-03-18 大塚製薬株式会社 シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
AR076262A1 (es) * 2009-04-06 2011-06-01 Eisai Inc Derivados heterociclicos de diazepin-2-ona, composiciones farmaceuticas y sus usos en el tratamiento del cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US5464826A (en) * 1984-12-04 1995-11-07 Eli Lilly And Company Method of treating tumors in mammals with 2',2'-difluoronucleosides
US6933287B1 (en) * 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOUFFARD, D. Y. et al., Biochemical Pharmacology. 1993, vol. 45, no. 9, pages 1857-1861 *
LALIBERTE, J. et al., Cancer Chemotherapy and Pharmacology. 1992, vol. 30, no. 1, pages 7-11 *
LEMAIRE, M. et al., Cancer Chemotherapy and Pharmacology. published online 2008, vol. 63, no. 3, pages 411-416 *
LIU, P. S. et al., Journal of Medicinal Chemistry. 1981, vol. 24, no. 6, pages 662-666 *
LUDEK, O. R. et al., Nucleic Acids Symposium Series (2004). 2008, no. 52, pages 659-660 *
MARQUEZ, V. E. et al., Journal of Medicinal Chemistry. 1980, vol. 23, no. 7, pages 713-715 *

Also Published As

Publication number Publication date
US8329666B2 (en) 2012-12-11
US20100279967A1 (en) 2010-11-04
ES2628580T3 (es) 2017-08-03
WO2010118010A1 (en) 2010-10-14
UY32546A (es) 2010-10-29
EP2416780A1 (en) 2012-02-15
AU2010234641A1 (en) 2011-11-10
TWI503121B (zh) 2015-10-11
AR076263A1 (es) 2011-06-01
CA2757744C (en) 2018-02-13
JP5730854B2 (ja) 2015-06-10
JO3262B1 (ar) 2018-09-16
EP2416780B1 (en) 2017-03-08
JP2012522841A (ja) 2012-09-27
CA2757744A1 (en) 2010-10-14
TW201102072A (en) 2011-01-16

Similar Documents

Publication Publication Date Title
AU2010234641B2 (en) Combination of decitabine with cytidine deaminase inhibitor and use thereof in the treatment of cancer
AU2016213880B2 (en) Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
AU2016213881B2 (en) (2’-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer
US9040501B2 (en) Compositions and methods for treating cancer
AU2008312435B8 (en) 2 ' -fluoro-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors
AU2008312435A1 (en) 2 ' -fluoro-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.

Free format text: FORMER APPLICANT(S): EISAI INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAIHO PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER(S): OTSUKA PHARMACEUTICAL CO., LTD.